Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT. Valenzano KJ, et al. Among authors: mark l. Neuropharmacology. 2005 Apr;48(5):658-72. doi: 10.1016/j.neuropharm.2004.12.008. Neuropharmacology. 2005. PMID: 15814101
Pharmacological characterisation of a rat model of incisional pain.
Whiteside GT, Harrison J, Boulet J, Mark L, Pearson M, Gottshall S, Walker K. Whiteside GT, et al. Among authors: mark l. Br J Pharmacol. 2004 Jan;141(1):85-91. doi: 10.1038/sj.bjp.0705568. Epub 2003 Nov 3. Br J Pharmacol. 2004. PMID: 14597606 Free PMC article.
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
Whiteside GT, Harrison JE, Pearson MS, Chen Z, Fundytus ME, Rotshteyn Y, Turchin PI, Pomonis JD, Mark L, Walker K, Broglé KC. Whiteside GT, et al. Among authors: mark l. J Pharmacol Exp Ther. 2004 Aug;310(2):793-9. doi: 10.1124/jpet.103.063560. Epub 2004 Mar 30. J Pharmacol Exp Ther. 2004. PMID: 15054116
A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, Turchin PI, Mark L, Garrison AE, Valenzano KJ. Whiteside GT, et al. Among authors: mark l. Eur J Pharmacol. 2005 Dec 28;528(1-3):65-72. doi: 10.1016/j.ejphar.2005.10.043. Epub 2005 Nov 28. Eur J Pharmacol. 2005. PMID: 16316650
We have previously reported that administration of the selective cannabinoid CB2 receptor agonist GW405833 (2,3-dichloro-phenyl)-[5-methoxy-2-methyl-3-(2-morpholin-4-yl-ethyl)-indol-1-yl]-methanone) to rats elicits potent and efficacious antihyperalgesic effects against neuropath …
We have previously reported that administration of the selective cannabinoid CB2 receptor agonist GW405833 (2,3-dichloro-phenyl)-[5-methoxy- …
N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain.
Pomonis JD, Harrison JE, Mark L, Bristol DR, Valenzano KJ, Walker K. Pomonis JD, et al. Among authors: mark l. J Pharmacol Exp Ther. 2003 Jul;306(1):387-93. doi: 10.1124/jpet.102.046268. Epub 2003 Apr 29. J Pharmacol Exp Ther. 2003. PMID: 12721336
Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states.
Ilyin VI, Pomonis JD, Whiteside GT, Harrison JE, Pearson MS, Mark L, Turchin PI, Gottshall S, Carter RB, Nguyen P, Hogenkamp DJ, Olanrewaju S, Benjamin E, Woodward RM. Ilyin VI, et al. Among authors: mark l. J Pharmacol Exp Ther. 2006 Sep;318(3):1083-93. doi: 10.1124/jpet.106.104737. Epub 2006 May 25. J Pharmacol Exp Ther. 2006. PMID: 16728593
WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression.
Whiteside GT, Dwyer JM, Harrison JE, Beyer CE, Cummons T, Manzino L, Mark L, Johnston GH, Strassle BW, Adedoyin A, Lu P, Piesla MJ, Pulicicchio CM, Erve JC, Platt BJ, Hughes ZA, Rogers KE, Deecher DC, Trybulski EJ, Kennedy JD, Zhang P, Leventhal L. Whiteside GT, et al. Among authors: mark l. Br J Pharmacol. 2010 Jul;160(5):1105-18. doi: 10.1111/j.1476-5381.2010.00690.x. Br J Pharmacol. 2010. PMID: 20590604 Free PMC article.
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
O'Neill DJ, Adedoyin A, Bray JA, Deecher DC, Fensome A, Goldberg JA, Harrison J, Leventhal L, Mann C, Mark L, Nogle L, Sullivan NR, Spangler TB, Terefenko EA, Trybulski EJ, Uveges AJ, Vu A, Whiteside GT, Zhang P. O'Neill DJ, et al. Among authors: mark l. J Med Chem. 2011 Oct 13;54(19):6824-31. doi: 10.1021/jm200733r. Epub 2011 Sep 14. J Med Chem. 2011. PMID: 21916421
527 results